Breaking News, Collaborations & Alliances

X-BODY, Hengrui in Chinese AMD Alliance

To develop novel antibody program from X-BODY platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

X-BODY Biosciences has entered an exclusive alliance with Jiangsu Hengrui Medicine Co. under which Hengrui will develop and commercialize a novel antibody program generated from X-BODY’s antibody platform for Age-related Macular Degeneration (AMD) in China (including, Taiwan, Macao, and Hong Kong).   Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts. X-BODY retains all development and commercialization rights outside Greater China. Fi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters